Core Viewpoint - Pliant Therapeutics is gaining attention due to promising interim trial results for its cancer therapy, PLN-101095, despite a significant decline in its stock price [1][8]. Group 1: Trial Results - Pliant Therapeutics released interim data from its Phase 1 dose escalation trial of PLN-101095, which was evaluated in combination with Merck's Keytruda for patients with immune checkpoint inhibitor-refractory advanced or metastatic solid tumors [2]. - In a heavily pretreated patient population, PLN-101095 demonstrated antitumor activity, with four responders identified, including one confirmed complete response and three partial responses [3][4]. - Clinical responses were observed in various cancer types, including cholangiocarcinoma, melanoma, head and neck squamous cell carcinoma, and non-small cell lung cancer [4]. Group 2: Patient Outcomes - The median time on treatment for patients was 15 months, with 60% of secondary refractory patients showing stable disease or tumor reduction [5]. - All responding patients exhibited significant increases in plasma interferon gamma (IFN-γ) levels after a 14-day monotherapy run-in period, while non-responders did not show meaningful increases [5]. Group 3: Safety and Future Plans - PLN-101095 was generally well tolerated across all tested doses and exhibited a dose-dependent pharmacokinetic profile [6]. - Pliant plans to accelerate the development of PLN-101095 with a Phase 1b indication expansion trial set to begin in 2026, focusing on non-small cell lung cancer and other tumor types [7].

Core Insights - Biotech stocks experienced significant gains in after-hours trading on September 9, 2025, driven by clinical updates, insider buying, and investor conference appearances across several small- and mid-cap companies [1] Company Summaries - **Immutep Ltd. (IMMP)**: Shares rose by 4.37% to $1.67 after-hours, following a decline of 6.98% during regular trading. The stock's rebound was fueled by the acceptance of data from its EFTISARC-NEO Phase II trial for oral presentation at CTOS 2025, focusing on a rare cancer with high unmet need [2][3] - **Nautilus Biotechnology Inc. (NAUT)**: Shares surged by 12.25% to $0.7521 after-hours, recovering from a 4.42% decline in regular trading. The increase was attributed to insider buying by CEO Sujal M. Patel, who purchased 83,500 shares, signaling confidence in the company [4][5] - **Pliant Therapeutics Inc. (PLRX)**: The stock ended regular trading at $1.75, up 1.16%, and jumped 16.00% to $2.03 after-hours. The upcoming third-quarter earnings report on November 6, 2025, is expected to provide updates on its lead candidate targeting idiopathic pulmonary fibrosis [6][7] - **Jin Medical International Ltd. (ZJYL)**: Shares closed at $0.6532, gaining 3.65% during regular trading and rising 7.15% to $0.6999 after-hours. The catalyst for this movement was the announcement of expanded production capabilities in China, aimed at enhancing global delivery of medical equipment [7][8] - **Phio Pharmaceuticals Corp. (PHIO)**: The stock rose 8.20% to $2.64 after-hours, building on a 13.49% increase during regular trading. The momentum was driven by participation in the H.C. Wainwright 27th Annual Global Investment Conference, where updates on its Phase 1b clinical trial for PH-762 will be presented [8][9] - **Kura Oncology Inc. (KURA)**: Shares increased by 6.12% to $8.50 after-hours, following a 1.60% decline in regular trading. The rally was linked to the company's presentation at the H.C. Wainwright conference, highlighting key developments and upcoming regulatory milestones for Ziftomenib [10][11][12]

Core Viewpoint - Pliant Therapeutics, Inc is under investigation for potential securities fraud and unlawful business practices following a significant stock price drop after pausing a clinical trial for its drug bexotegrast [1][3]. Company Developments - On February 7, 2025, Pliant announced a voluntary pause in enrollment and dosing for the BEACON-IPF Phase 2b trial of bexotegrast due to recommendations from the independent Data Safety Monitoring Board [3]. - Following this announcement, analysts from Wells Fargo and Citi downgraded Pliant, indicating uncertainty regarding the future of bexotegrast [3]. Stock Performance - After the announcement of the trial pause, Pliant's stock price fell by $4.72 per share, representing a 60.59% decrease, closing at $3.07 per share on February 10, 2025 [4].

Core Viewpoint - Pliant Therapeutics, Inc. (PLRX) has received a Zacks Rank upgrade to 2 (Buy) due to an upward trend in earnings estimates, indicating potential for stock price increase [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system emphasizes the importance of changing earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates for Pliant Therapeutics suggest an improvement in the company's underlying business, likely leading to increased investor interest and stock price appreciation [5][10]. Earnings Estimate Revisions - For the fiscal year ending December 2025, Pliant Therapeutics is expected to report earnings of -$2.72 per share, reflecting a 21.6% change from the previous year [8]. - Over the past three months, the Zacks Consensus Estimate for Pliant Therapeutics has increased by 32.5%, indicating positive sentiment among analysts [8]. Zacks Rank System - The Zacks Rank system classifies stocks based on earnings estimate revisions, with only the top 20% of stocks receiving a 'Strong Buy' or 'Buy' rating, highlighting their potential for market-beating returns [9][10]. - Pliant Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting favorable earnings estimate revisions and potential for stock price growth [10].

Core Insights - Pliant Therapeutics will present three scientific posters at the 2025 American Thoracic Society (ATS) International Conference in San Francisco from May 16-21, 2025 [1][2]. Group 1: Presentations at ATS Conference - Pliant has been selected for a featured oral presentation at the ATS 2025 Mini Symposiums program [2]. - The oral presentation titled "Characterizing the Antifibrotic Activity of Bexotegrast on Distinct Fibroblast Populations in PCLS From Multiple ILD Subtypes" will be presented by Dr. Johanna Schaub on May 19, 2025, from 2:15 p.m. to 4:15 p.m. Pacific Time [3]. - Two posters will be presented on May 21, 2025, focusing on plasma proteome analysis and single-cell profiling related to antifibrotic effects of Bexotegrast, both scheduled from 8:15 a.m. to 10:15 a.m. Pacific Time [3]. Group 2: Company Overview - Pliant Therapeutics is a late-stage biopharmaceutical company specializing in novel therapeutics for fibrotic diseases [4]. - The lead product candidate, Bexotegrast (PLN-74809), is an oral small molecule targeting idiopathic pulmonary fibrosis (IPF) and has received Fast Track and Orphan Drug Designations from the FDA [4]. - Pliant is also developing PLN-101095 for solid tumors and has regulatory clearance for a Phase 1 study of PLN-101325 targeting muscular dystrophies [4].

Core Insights - Pliant Therapeutics Inc. (PLRX) is a biotech company focused on developing therapeutics for fibrotic diseases and is currently in a cash-rich position despite facing a significant setback with its lead drug candidate [1] Company Overview - Pliant Therapeutics is engaged in the discovery and development of treatments specifically targeting fibrotic diseases [1] - The company has a strong cash position, which may provide it with the necessary resources to navigate challenges [1] Investment Perspective - The company is considered attractive for investors looking for small-cap stocks with high upside potential relative to downside risk [1] - The investment approach is value-based, with an openness to exploring special situations and short opportunities [1]

Core Insights - Pliant Therapeutics, Inc. announced promising interim results from its Phase 1 clinical trial of PLN-101095, showing a 50% objective response rate in patients with advanced or metastatic solid tumors who are refractory to immune checkpoint inhibitors [2][5][6] Group 1: Clinical Trial Details - The trial is evaluating PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, in combination with pembrolizumab in patients with ICI-refractory tumors [2][7] - Three partial responses were observed in cohort three at the highest tested dose of 1000 mg administered orally twice daily [2][5] - The trial has enrolled nine patients across three cohorts, with treatment durations of 14 days followed by combination therapy [3][5] Group 2: Efficacy Observations - Among the six patients treated at the 1000 mg BID dose, three confirmed partial responses were noted, with significant reductions in tumor sizes: 74% for NSCLC, 48% for cholangiocarcinoma, and 42% for melanoma [5][6] - Initial partial responses were observed at Week 10 for NSCLC, Week 34 for cholangiocarcinoma, and Week 18 for melanoma [5] Group 3: Safety and Tolerability - PLN-101095 was generally well tolerated across all doses tested, indicating a favorable safety profile [2][5][6] - The ongoing trial is currently enrolling the fourth cohort, which will evaluate PLN-101095 at a different dosing schedule of 1000 mg three times daily [6] Group 4: Company Background - Pliant Therapeutics is focused on developing novel therapeutics for fibrotic diseases, with PLN-101095 being a key candidate for treating solid tumors [8] - The company has received regulatory designations for its lead product candidate, bexotegrast, indicating its commitment to advancing innovative treatments [8]

Core Viewpoint - Pliant Therapeutics has adopted a limited duration stockholder rights agreement to protect stockholder interests in response to recent stock accumulations [1][2]. Group 1: Rights Agreement Details - The Rights Agreement aims to prevent any entity from gaining control of Pliant through open market accumulation without compensating all stockholders appropriately [2]. - Pliant will issue one preferred share purchase right for each outstanding share of common stock to stockholders of record on March 25, 2025 [3]. - The Rights Agreement will expire on March 11, 2026, unless terminated earlier [3]. Group 2: Exercisability and Terms - Rights become exercisable if an acquiring person obtains 10% (or 20% for certain investors) of the outstanding shares without Board approval, allowing other right holders to purchase additional shares at a 50% discount [4]. - In the event of a merger after an unapproved acquisition, right holders can purchase shares of the acquiring company at a 50% discount [4]. - The Board may redeem the rights at $0.001 per right, and existing ownership percentages prior to the Rights Agreement announcement will be grandfathered under certain conditions [5]. Group 3: Company Overview - Pliant Therapeutics is a late-stage biopharmaceutical company focused on developing therapeutics for fibrotic diseases, with its lead product candidate, bexotegrast, in development for idiopathic pulmonary fibrosis [7]. - Bexotegrast has received Fast Track and Orphan Drug Designations from the FDA and the European Medicines Agency [7]. - Pliant is also conducting Phase 1 studies for other drug candidates targeting solid tumors and muscular dystrophies [7].

Core Viewpoint - Pliant Therapeutics has discontinued the BEACON-IPF Phase 2b trial based on recommendations from an independent data safety monitoring board (DSMB) and an outside expert panel due to an imbalance in adverse events, despite early signs of efficacy in forced vital capacity (FVC) [2][3] Group 1: Clinical Trials and Programs - The BEACON-IPF trial, a 52-week multinational study evaluating bexotegrast in patients with idiopathic pulmonary fibrosis (IPF), has been halted following safety concerns [2] - The Phase 1 trial of PLN-101095, an oral small molecule targeting solid tumors, continues to enroll patients, with interim data expected in Q1 2025 [3] - PLN-101325, a monoclonal antibody for muscular dystrophies, is Phase 1 ready with clinical trial approval in Australia [4] Group 2: Corporate Developments - Delphine Imbert, Ph.D., has been appointed as Chief Technical Officer, bringing 25 years of experience in product development and manufacturing [5] Group 3: Financial Results - Research and development expenses for Q4 2024 were $38.8 million, up from $33.2 million in Q4 2023, primarily due to costs associated with the BEACON-IPF trial [6] - General and administrative expenses increased to $14.5 million from $13.9 million year-over-year, driven by higher employee-related costs [6] - The net loss for Q4 2024 was $49.7 million, compared to $41.1 million in the same quarter of the previous year, attributed to increased operating expenses and reduced interest income [6] - As of December 31, 2024, the company had cash and short-term investments totaling $357.2 million, expected to fund operations for the next 12 months [6]